Determining the docosahexaenoic acid dose to obtain plasma and erythrocyte phospholipid fatty acid profiles in preterm infants comparable to term infant profiles: a dose response pilot study.
Not Applicable
Completed
- Conditions
- Preterm infantsDiet and Nutrition - Other diet and nutrition disordersReproductive Health and Childbirth - Complications of newborn
- Registration Number
- ACTRN12610000382077
- Lead Sponsor
- Women's and Children's Health Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Infants born less than 33 weeks gestation after one but before five days of commencing any enteral feeds and with parental/guardian consent. Multiple births will be eligible and will be randomised individually. Women providing breast milk for their infant not taking DHA supplements or willing to stop taking supplements for duration study.
Exclusion Criteria
Infants with major congenital or chromosomal abnormalities. Infants likely to be transferred to remote locations where weekly blood tests can’t be done.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood (erythrocyte and plasma) phospholipid DHA levels analysed using gas chromotography.[Day 0, 7, 14, 21, 28]
- Secondary Outcome Measures
Name Time Method Tolerance of the enteral emulsions will be determined by comparing the number of days to reach full enteral feeds (>=150 mls/kg/day) and number of days in which one or more feeds were stopped.[Daily from study start to end (28 days)]